Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Buser

Showing results (91-100 of 104) with videos related to

Pageof 11
Sort By:
Bioorganic & Medicinal Chemistry Letters|January 28, 2006
Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSPMark E Fraley, Robert M Garbaccio, Kenneth L Arrington, et al.
Bioorganic & Medicinal Chemistry Letters|January 28, 2006
Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubilityRobert M Garbaccio, Mark E Fraley, Edward S Tasber, et al.
Bioorganic & Medicinal Chemistry Letters|September 19, 2006
3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6Mark E Fraley, Justin T Steen, Edward J Brnardic, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2007
Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitorsEdward J Brnardic, Robert M Garbaccio, Mark E Fraley, et al.
Bioorganic & Medicinal Chemistry Letters|July 19, 2001
Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferaseD C Beshore, I M Bell, C J Dinsmore, et al.
Journal of Medicinal Chemistry|August 25, 2001
Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potencyI M Bell, S N Gallicchio, M Abrams, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2007
Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSPRobert M Garbaccio, Edward S Tasber, Lou Anne Neilson, et al.
Journal of Medicinal Chemistry|June 27, 2008
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancerChristopher D Cox, Paul J Coleman, Michael J Breslin, et al.
Vox Sanguinis|September 21, 2017
Vox Sanguinis International Forum on platelet cryopreservationC S Cohn, L J Dumont, M Lozano, et al.
Vox Sanguinis|September 21, 2017
Vox Sanguinis International Forum on platelet cryopreservation: SummaryC S Cohn, L J Dumont, M Lozano, et al.
Pageof 11

Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
Bioorganic & Medicinal Chemistry Letters|January 28, 2006
Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSPMark E Fraley, Robert M Garbaccio, Kenneth L Arrington, et al.
Bioorganic & Medicinal Chemistry Letters|January 28, 2006
Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubilityRobert M Garbaccio, Mark E Fraley, Edward S Tasber, et al.
Bioorganic & Medicinal Chemistry Letters|September 19, 2006
3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6Mark E Fraley, Justin T Steen, Edward J Brnardic, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2007
Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitorsEdward J Brnardic, Robert M Garbaccio, Mark E Fraley, et al.
Bioorganic & Medicinal Chemistry Letters|July 19, 2001
Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferaseD C Beshore, I M Bell, C J Dinsmore, et al.
Journal of Medicinal Chemistry|August 25, 2001
Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potencyI M Bell, S N Gallicchio, M Abrams, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2007
Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSPRobert M Garbaccio, Edward S Tasber, Lou Anne Neilson, et al.
Journal of Medicinal Chemistry|June 27, 2008
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancerChristopher D Cox, Paul J Coleman, Michael J Breslin, et al.
Vox Sanguinis|September 21, 2017
Vox Sanguinis International Forum on platelet cryopreservationC S Cohn, L J Dumont, M Lozano, et al.
Vox Sanguinis|September 21, 2017
Vox Sanguinis International Forum on platelet cryopreservation: SummaryC S Cohn, L J Dumont, M Lozano, et al.
Pageof 11